Philip W. Hinds

Prof. Philip W. Hinds


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
PHPhilip W. Hinds
Philip W. Hinds
JPJodie Pietruska
Jodie Pietruska
Cellular senescence has emerged as a potent tumor suppression mechanism that restrains proliferation of cells at risk for malignant transformation. Although senescent cells have permanently exited the cell cycle, their presence can have detrimental effects on the surrounding tissue, largely due to the development of the senescence-associated secretory phenotype (SASP). Here, we review the tumor-suppressive and tumor-promoting consequences of the senescence response, focusing on the SASP as a key mediator of this dichotomy. Accumulating evidence suggests that the persistence of senescent cells can exacerbate the development of a pro-inflammatory, immunosuppressive microenvironment that can favor tumorigenesis. Given that senescence of tumor and stromal cells is a frequent outcome of anti-cancer therapy, approaches that harness the growth inhibitory effects of senescence while limiting its detrimental effects are likely to have great clinical potential.

25 March 2016 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
SBSarah E Ballatori
Sarah E Ballatori
PHPhilip W. Hinds
Philip W. Hinds
Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, affecting ~560 young patients in the United States annually. The term OS describes a diverse array of subtypes with varying prognoses, but the majority of tumors are high grade and aggressive. Perhaps because the true etiology of these aggressive tumors remains unknown, advances in OS treatment have reached a discouraging plateau, with only incremental improvements over the past 40 years. Thus, research surrounding the pathogenesis of OS is essential, as it promises to unveil novel therapeutic targets that can attack tumor cells with greater specificity and lower toxicity. Among the candidate molecular targets in OS, the retinoblastoma (RB) pathway demonstrates the highest frequency of inactivation and thus represents a particularly promising avenue for molecular targeted therapy. This review examines the present thinking and practices in OS treatment and specifically highlights the relevance of the RB pathway in osteosarcomagenesis. Through further investigation into RB pathway-related novel therapeutic targets, we believe that a near-term breakthrough in improved OS prognosis is possible.

2 June 2015 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
CLChi Luo
Chi Luo
JPJodie R. Pietruska
Jodie R. Pietruska
JSJinghao Sheng
Jinghao Sheng
RBRoderick T. Bronson
Roderick T. Bronson
MHMiaofen G. Hu
Miaofen G. Hu
PHPhilip W. Hinds
Philip W. Hinds

23 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ABAbraham L Bayer
Abraham L Bayer
JPJodie Pietruska
Jodie Pietruska
JFJaymes Farrell
Jaymes Farrell
SMSiobhan McRee
Siobhan McRee
PAPilar Alcaide
Pilar Alcaide
PHPhilip W. Hinds
Philip W. Hinds
Cellular senescence is a carefully regulated process of proliferative arrest accompanied by functional and morphologic changes. Senescence allows damaged cells to avoid neoplastic proliferation; however, the induction of the senescence-associated secretory phenotype (SASP) can promote tumor growth. The complexity of senescence may limit the efficacy of anti-neoplastic agents, such as CDK4/6 inhibitors (Cdk4/6i), that induce a senescence-like state in tumor cells. The AKT kinase family, which contains three isoforms that play both unique and redundant roles in cancer progression, is commonly hyperactive in many cancers including melanoma and has been implicated in the regulation of senescence. To interrogate the role of AKT isoforms in Cdk4/6i-induced cellular senescence, we generated isoform-specific AKT knockout human melanoma cell lines. We found that the CDK4/6i Palbociclib induced a form of senescence in these cells that was dependent on AKT1. We then evaluated the activity of the cGAS-STING pathway, recently implicated in cellular senescence, finding that cGAS-STING function was dependent on AKT1, and pharmacologic inhibition of cGAS had little effect on senescence. However, we found SASP factors to require NF-κB function, in part dependent on a stimulatory phosphorylation of IKKα by AKT1. In summary, we provide the first evidence of a novel, isoform-specific role for AKT1 in therapy-induced senescence in human melanoma cells acting through NF-κB but independent of cGAS.

12 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SMSiobhan McRee
Siobhan McRee
ABAbraham L Bayer
Abraham L Bayer
JPJodie Pietruska
Jodie Pietruska
PTPhilip N. Tsichlis
Philip N. Tsichlis
PHPhilip W. Hinds
Philip W. Hinds
Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer due to its highly metastatic nature. Melanomas harboring oncogenic BRAFV600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain about whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and we investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT isoform-specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo, whereas AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby the inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that the elucidation of AKT2-specific functions in metastasis might inform therapeutic strategies to improve treatment options for melanoma patients.

1 July 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
PHPhilip W. Hinds
Philip W. Hinds
Summary: Germline deletion of RB1, the gene encoding the retinoblastoma tumor-suppressor protein pRB, predisposes to eye tumor formation upon loss of the remaining wild-type allele. Many functions affecting cell-cycle control, cell-cycle exit, and numerous other processes involved in the transformed phenotype have been ascribed to pRB, and deregulation of these processes is generally thought to result from complete loss of pRB in both hereditary and sporadic tumors in multiple tissues. Loss of just one allele of RB1 is now shown to lead to replication stress and aneuploidy in both mouse and human cells, and the mechanism through which this haploinsufficient phenotype is achieved may open up new opportunities for interceding both in tumor initiation and in treatment of extant tumors. Cancer Discov; 4(7); 764–5. ©2014 AACR.